Aspirin (Synonyms: 阿司匹林; Acetylsalicylic Acid; ASA)

目录号: HY-14654 纯度: 99.82%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Aspirin (Acetylsalicylic Acid) 是一种口服有效的不可逆的环氧合酶 COX-1 和 COX-2 抑制剂，IC₅₀ 分别为 5 和 210 μg/mL. Aspirin 诱导细胞凋亡 (apoptosis)。Aspirin 可抑制 NF-κB 的活化。Aspirin 还抑制血小板前列腺素合成酶 (prostaglandin synthetase)，可预防冠状动脉和脑血管血栓形成。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Aspirin Chemical Structure

CAS No. : 50-78-2

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥500	In-stock
500 mg	￥400	In-stock
1 g	￥500	In-stock
5 g	￥800	In-stock
10 g		询价
50 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Aspirin:

Aspirin-d₃ In-stock
Aspirin-d₄ In-stock
Aspirin Aluminum In-stock
Aspirin (Standard) In-stock
Aspirin lithium 询价
Aspirin calcium 询价

MCE 顾客使用本产品发表的 21 篇科研文献

: Aspirin purchased from MCE. Usage Cited in: Cell Death Dis. 2018 Aug 28;9(9):847. [Abstract]; HIPK2 expression is upregulated by treatments with 5 μM Resveratrol, 30 μM Aspirin, 10 μM Vitamin E, and 15 μM Ursolic acid for another 16 h after the LPS treatment, as analysed by western blotting.

Aspirin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 COX 亚型特异性产品:

查看所有亚型

COX COX-1 COX-2 COX-3

查看 NF-κB 亚型特异性产品:

查看所有亚型

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

查看 Caspase 亚型特异性产品:

查看所有亚型

Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

查看 p38 MAPK 亚型特异性产品:

查看所有亚型

p38 MAPK p38α p38β MAPK13 p38δ p38γ

生物活性
纯度 & 产品资料
参考文献

生物活性

Aspirin (Acetylsalicylic Acid) is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC₅₀ values of 5 and 210 μg/mL, respectively. Aspirin induces apoptosis. Aspirin inhibits the activation of NF-κB. Aspirin also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis^[1]^[2]^[3]^[4]^[5]^[6].

IC₅₀ & Target^[1]

COX-1

27.75 μM (IC₅₀)

COX-2

1.17 mM (IC₅₀)

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 5000000 nM Compound: ASA	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 22916316]
Bel-7402	IC₅₀	> 100 μM Compound: Aspirin	Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK-8 assay	[PMID: 28301815]
Bel7402/5-FU	IC₅₀	> 100 μM Compound: Aspirin	Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by CCK-8 assay Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by CCK-8 assay	[PMID: 28301815]
BGC-823	IC₅₀	> 50 μM Compound: Aspirin	Cytotoxicity against human BGC-823 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Cytotoxicity against human BGC-823 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 33799070]
BXPC-3	IC₅₀	> 5000000 nM Compound: ASA	Cytotoxicity against human BxPC3 cells expressing COX1 and COX2 after 24 hrs by MTT assay Cytotoxicity against human BxPC3 cells expressing COX1 and COX2 after 24 hrs by MTT assay	[PMID: 22916316]
Caco-2	IC₅₀	> 50 μM Compound: Aspirin	Cytotoxicity against human Caco2 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Cytotoxicity against human Caco2 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 33799070]
DLD-1	IC₅₀	> 100 μM Compound: 1; ASA	Antiproliferative activity against human DLD1 cells after 72 hrs by MTT assay Antiproliferative activity against human DLD1 cells after 72 hrs by MTT assay	[PMID: 30429977]
DU-145	IC₅₀	> 100 μM Compound: 1; ASA	Antiproliferative activity against human DU-145 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human DU-145 cells incubated for 48 hrs by MTT assay	[PMID: 36257283]
Erythrocyte	IC₅₀	166 mM Compound: Aspirin	Antiinflammatory activity in human erythrocytes assessed as inhibition of hypotonic solution-induced hemolysis after 10 mins by spectrophotometry Antiinflammatory activity in human erythrocytes assessed as inhibition of hypotonic solution-induced hemolysis after 10 mins by spectrophotometry	[PMID: 25638040]
HaCaT	IC₅₀	21.27 μM Compound: ASA	Antiinflammatory activity against human HaCaT cells assessed as inhibition of UVB irradiation-induced PGE2 production measured after 2 hrs by ELISA Antiinflammatory activity against human HaCaT cells assessed as inhibition of UVB irradiation-induced PGE2 production measured after 2 hrs by ELISA	[PMID: 35172097]
HaCaT	IC₅₀	30.4 μM Compound: Aspirin	Inhibition of ultraviolet B-irradiation upregulated of prostaglandin E2 production in human HaCaT cells measured after 2 hrs by ELISA Inhibition of ultraviolet B-irradiation upregulated of prostaglandin E2 production in human HaCaT cells measured after 2 hrs by ELISA	[PMID: 34463498]
HCT-116	IC₅₀	> 60 μM Compound: 3	Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 24 hrs by MTT assay	[PMID: 26204233]
HCT-15	IC₅₀	> 5000000 nM Compound: Aspirin	Cytotoxicity against human HCT15 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human HCT15 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 26323873]
HCT-15	IC₅₀	> 5000000 nM Compound: ASA	Cytotoxicity against COX deficient human HCT15 cells after 24 hrs by MTT assay Cytotoxicity against COX deficient human HCT15 cells after 24 hrs by MTT assay	[PMID: 22916316]
HCT-8	IC₅₀	> 100 μM Compound: 1; ASA	Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 30429977]
HCT-8	IC₅₀	> 100 μM Compound: 2; ASA	Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 30037494]
HCT-8	IC₅₀	15.6 μM Compound: 2; ASA	Antiproliferative activity against human HCT8 cells after 72 hrs in presence of cinnamaldehyde by MTT assay Antiproliferative activity against human HCT8 cells after 72 hrs in presence of cinnamaldehyde by MTT assay	[PMID: 30037494]
HEK293	IC₅₀	10.2 mM Compound: 4	Cytotoxicity against HEK293 cells harboring pendrin P123S mutant after 72 hrs by MTT assay Cytotoxicity against HEK293 cells harboring pendrin P123S mutant after 72 hrs by MTT assay	[PMID: 28341401]
HepG2	IC₅₀	3841 μM Compound: Aspirin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23153797]
HT-29	IC₅₀	> 100 μM Compound: 1; ASA	Antiproliferative activity against human HT-29 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells incubated for 48 hrs by MTT assay	[PMID: 36257283]
HT-29	EC₅₀	> 1000 μM Compound: ASA	Apoptosis induction in human HT29 cells after 24 hrs Apoptosis induction in human HT29 cells after 24 hrs	[PMID: 17441704]
HT-29	IC₅₀	> 50 μM Compound: ASA	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26750401]
HT-29	IC₅₀	> 50 μM Compound: ASA	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26750401]
HT-29	IC₅₀	> 50 μM Compound: ASA	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26750401]
HT-29	IC₅₀	> 5000000 nM Compound: Aspirin	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 26323873]
HT-29	IC₅₀	> 5000000 nM Compound: ASA	Cytotoxicity against human HT-29 cells expressing COX1 and COX2 after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells expressing COX1 and COX2 after 24 hrs by MTT assay	[PMID: 22916316]
HT-29	IC₅₀	> 60 μM Compound: 3	Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 24 hrs by MTT assay	[PMID: 26204233]
HUVEC	IC₅₀	5 mM Compound: Aspirin	Antiinflammatory activity in HUVEC assessed as inhibition of TNFalpha-induced ICAM1 expression measured after 6 hrs by FACS flow cytometry Antiinflammatory activity in HUVEC assessed as inhibition of TNFalpha-induced ICAM1 expression measured after 6 hrs by FACS flow cytometry	10.1039/C0MD00262C
Jurkat	IC₅₀	> 5000000 nM Compound: ASA	Cytotoxicity against human Jurkat cells expressing COX1 and COX2 after 24 hrs by MTT assay Cytotoxicity against human Jurkat cells expressing COX1 and COX2 after 24 hrs by MTT assay	[PMID: 22916316]
L02	IC₅₀	> 100 μM Compound: Aspirin	Antiproliferative activity against human LO2 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human LO2 cells after 72 hrs by CCK-8 assay	[PMID: 28301815]
LNCaP	IC₅₀	> 5000000 nM Compound: ASA	Cytotoxicity against human LNCAP cells after 24 hrs by MTT assay Cytotoxicity against human LNCAP cells after 24 hrs by MTT assay	[PMID: 22916316]
MCF7	IC₅₀	> 100 μM Compound: 1; ASA	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 36257283]
MCF7	IC₅₀	> 50 μM Compound: Aspirin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 33799070]
MCF7	IC₅₀	> 5000000 nM Compound: ASA	Cytotoxicity against human MCF7 cells expressing ER after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells expressing ER after 24 hrs by MTT assay	[PMID: 22916316]
MDA-MB-231	IC₅₀	> 50 μM Compound: ASA	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26750401]
MDA-MB-231	IC₅₀	> 50 μM Compound: ASA	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26750401]
MDA-MB-231	IC₅₀	> 50 μM Compound: ASA	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26750401]
MDA-MB-231	IC₅₀	> 5000000 nM Compound: ASA	Cytotoxicity against ER deficient human MDA-MB-231 cells after 24 hrs by MTT assay Cytotoxicity against ER deficient human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 22916316]
MDA-MB-231	IC₅₀	1510 μM Compound: Aspirin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 23153797]
Mesenchymal stem cells	EC₅₀	> 300 μM Compound: ASA	Induction of adiponectin secretion in human differentiated BMMSC cells measured at 5 day in the presence of IDX induction medium by ELISA Induction of adiponectin secretion in human differentiated BMMSC cells measured at 5 day in the presence of IDX induction medium by ELISA	[PMID: 35172097]
MIA PaCa-2	IC₅₀	> 5000000 nM Compound: ASA	Cytotoxicity against COX deficient human MIAPaCa2 cells after 24 hrs by MTT assay Cytotoxicity against COX deficient human MIAPaCa2 cells after 24 hrs by MTT assay	[PMID: 22916316]
Microglia	IC₅₀	3.12 μM Compound: aspirin	Antineuroinflammatory activity in LPS-stimulated rat microglia cells assessed as inhibition of PMA-stimulated TXB2 release preincubated for 15 mins measured 70 mins after PMA challenge Antineuroinflammatory activity in LPS-stimulated rat microglia cells assessed as inhibition of PMA-stimulated TXB2 release preincubated for 15 mins measured 70 mins after PMA challenge	[PMID: 22153874]
PANC-1	IC₅₀	> 50 μM Compound: ASA	Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26750401]
PANC-1	IC₅₀	> 50 μM Compound: ASA	Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26750401]
PANC-1	IC₅₀	> 50 μM Compound: ASA	Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26750401]
PANC-1	IC₅₀	7.45 x 10^-4 M Compound: 1, ASA	Cytotoxicity against human PANC1 cells after 48 hrs by alamar blue assay Cytotoxicity against human PANC1 cells after 48 hrs by alamar blue assay	[PMID: 22494617]
PANC-1	IC₅₀	9.75 x 10^-4 M Compound: 1, ASA	Cytotoxicity against human PANC1 cells after 24 hrs by alamar blue assay Cytotoxicity against human PANC1 cells after 24 hrs by alamar blue assay	[PMID: 22494617]
PC-3	IC₅₀	> 50 μM Compound: Aspirin	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 33799070]
PC-3	IC₅₀	7.71 x 10^-4 M Compound: 1, ASA	Cytotoxicity against human PC3 cells after 24 hrs by alamar blue assay Cytotoxicity against human PC3 cells after 24 hrs by alamar blue assay	[PMID: 22494617]
PC-3	IC₅₀	7.82 x 10^-4 M Compound: 1, ASA	Cytotoxicity against human PC3 cells after 48 hrs by alamar blue assay Cytotoxicity against human PC3 cells after 48 hrs by alamar blue assay	[PMID: 22494617]
Platelet	IC₅₀	> 100 μM Compound: Aspirin	Inhibition of thrombin-induced human platelet aggregation by light transmission aggregometer Inhibition of thrombin-induced human platelet aggregation by light transmission aggregometer	[PMID: 18547115]
Platelet	IC₅₀	> 1000 μM Compound: ASA	Antiplatelet activity against collagen A23187-induced platelet aggregation in human plasma preincubated for 2 mins before addition of inducer by turbidimetric method Antiplatelet activity against collagen A23187-induced platelet aggregation in human plasma preincubated for 2 mins before addition of inducer by turbidimetric method	[PMID: 23425969]
Platelet	IC₅₀	> 1000 μM Compound: ASA	Antiplatelet activity against collagen ADP-induced platelet aggregation in human plasma preincubated for 2 mins before addition of inducer by turbidimetric method Antiplatelet activity against collagen ADP-induced platelet aggregation in human plasma preincubated for 2 mins before addition of inducer by turbidimetric method	[PMID: 23425969]
Platelet	IC₅₀	> 50 μg/mL Compound: Aspirin	Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry	[PMID: 21106454]
Platelet	IC₅₀	> 500 μM Compound: ASA	Antiplatelet activity in guinea pig platelet rich plasma assessed as inhibition of ADP-induced aggregation by aggregometry Antiplatelet activity in guinea pig platelet rich plasma assessed as inhibition of ADP-induced aggregation by aggregometry	[PMID: 25194932]
Platelet	IC₅₀	> 500 μM Compound: ASA	Antiplatelet activity in guinea pig platelet rich plasma assessed as inhibition of U46619-induced aggregation by aggregometry Antiplatelet activity in guinea pig platelet rich plasma assessed as inhibition of U46619-induced aggregation by aggregometry	[PMID: 25194932]
Platelet	IC₅₀	> 500 μM Compound: ASA	Antiplatelet activity against guinea pig platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation measured within 3 hrs by turbidimetric method Antiplatelet activity against guinea pig platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation measured within 3 hrs by turbidimetric method	[PMID: 22189137]
Platelet	IC₅₀	0.14 mM Compound: ASP	Antiplatelet aggregation activity in rabbit platelets assessed as inhibition of arachidonic acid-induced platelet aggregation incubated for 5 mins prior to arachidonic acid-challenge measured within 5 mins by Born's turbidimetric analysis Antiplatelet aggregation activity in rabbit platelets assessed as inhibition of arachidonic acid-induced platelet aggregation incubated for 5 mins prior to arachidonic acid-challenge measured within 5 mins by Born's turbidimetric analysis	[PMID: 23509954]
Platelet	IC₅₀	0.15 mM Compound: ASP	Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet rich plasma by Born's turbidimetric method Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet rich plasma by Born's turbidimetric method	[PMID: 22827516]
Platelet	IC₅₀	0.88 mM Compound: ASP	Inhibition of adenosine diphosphate-induced platelet aggregation in rabbit platelet rich plasma by Born's turbidimetric method Inhibition of adenosine diphosphate-induced platelet aggregation in rabbit platelet rich plasma by Born's turbidimetric method	[PMID: 22827516]
Platelet	IC₅₀	1.11 μM Compound: Aspirin	Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 2 mins followed by arachidonic acid addition by turbidimetric method Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 2 mins followed by arachidonic acid addition by turbidimetric method	[PMID: 30590258]
Platelet	IC₅₀	13.58 μg/mL Compound: Aspirin	Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry	[PMID: 21106454]
Platelet	IC₅₀	153.2 μM Compound: Aspirin	Inhibition of collagen-induced human platelet aggregation by light transmission aggregometer Inhibition of collagen-induced human platelet aggregation by light transmission aggregometer	[PMID: 18547115]
Platelet	IC₅₀	18 mg/kg Compound: Aspirin	Inhibition of epinephrine hydrochloride-induced platelet aggregation in human platelet-rich plasma after 5 mins Inhibition of epinephrine hydrochloride-induced platelet aggregation in human platelet-rich plasma after 5 mins	[PMID: 114655]
Platelet	IC₅₀	183 μM Compound: ASA	Antiplatelet activity against collagen collagen-induced platelet aggregation in human plasma preincubated for 2 mins before addition of inducer by turbidimetric method Antiplatelet activity against collagen collagen-induced platelet aggregation in human plasma preincubated for 2 mins before addition of inducer by turbidimetric method	[PMID: 23425969]
Platelet	IC₅₀	20.3 μM Compound: aspirin	Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet-rich blood by turbidimetric method Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet-rich blood by turbidimetric method	[PMID: 8988600]
Platelet	IC₅₀	20.6 μM Compound: aspirin	Antiplatelets aggregatory activity in human platelets rich plasma assessed as inhibition of collagen-induced platelets aggregation by aggregometry Antiplatelets aggregatory activity in human platelets rich plasma assessed as inhibition of collagen-induced platelets aggregation by aggregometry	[PMID: 19821574]
Platelet	IC₅₀	25 μM Compound: Aspirin	Inhibition of ADP-induced platelet aggregation in human platelet-rich plasma after 5 mins Inhibition of ADP-induced platelet aggregation in human platelet-rich plasma after 5 mins	[PMID: 114655]
Platelet	IC₅₀	27 μM Compound: Aspirin	Antiplatelet activity against washed rabbit platelet assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins before arachidonic acid challenge Antiplatelet activity against washed rabbit platelet assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins before arachidonic acid challenge	[PMID: 11374966]
Platelet	IC₅₀	30.5 μM Compound: Aspirin	Antiplatelet activity against rabbit platelet assessed as inhibition of collagen-induced platelet aggregation preincubated for 3 mins by turbidimetric method Antiplatelet activity against rabbit platelet assessed as inhibition of collagen-induced platelet aggregation preincubated for 3 mins by turbidimetric method	[PMID: 8759164]
Platelet	IC₅₀	31 μM Compound: Aspirin	Inhibition of collagen-induced platelet aggregation in human platelet-rich plasma after 5 mins Inhibition of collagen-induced platelet aggregation in human platelet-rich plasma after 5 mins	[PMID: 114655]
Platelet	IC₅₀	32.7 μM Compound: Aspirin	Antiplatelet activity against rabbit platelet assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins by turbidimetric method Antiplatelet activity against rabbit platelet assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins by turbidimetric method	[PMID: 8759164]
Platelet	IC₅₀	37.6 μM Compound: ASA	Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 2 mins followed by arachidonic acid addition by turbidimetric method relative to control Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 2 mins followed by arachidonic acid addition by turbidimetric method relative to control	[PMID: 28453995]
Platelet	ED₅₀	4.5 mg/kg Compound: aspirin	Inhibition of bovine collagen-induced platelet aggregation isolated from po treated Hartley guinea pig after 1 hr treatment Inhibition of bovine collagen-induced platelet aggregation isolated from po treated Hartley guinea pig after 1 hr treatment	[PMID: 214552]
Platelet	IC₅₀	4.5 μM Compound: Acetylsalicylic acid	Antiplatelet activity in platelet rich plasma (unknown origin) assessed as inhibition of collagen-induced platelet aggregation incubated for 5 mins by aggregometer analysis Antiplatelet activity in platelet rich plasma (unknown origin) assessed as inhibition of collagen-induced platelet aggregation incubated for 5 mins by aggregometer analysis	[PMID: 37054760]
Platelet	IC₅₀	45 μM Compound: ASA	Antiplatelet activity in guinea pig platelet rich plasma assessed as inhibition of arachidonic acid-induced aggregation by aggregometry Antiplatelet activity in guinea pig platelet rich plasma assessed as inhibition of arachidonic acid-induced aggregation by aggregometry	[PMID: 25194932]
Platelet	IC₅₀	45 μM Compound: ASA	Antiplatelet activity against guinea pig platelet-rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation measured within 3 hrs by turbidimetric method Antiplatelet activity against guinea pig platelet-rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation measured within 3 hrs by turbidimetric method	[PMID: 22189137]
Platelet	IC₅₀	5 μM Compound: Aspirin	Antiplatelet activity in human platelet-rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation treated for 5 mins prior to arachidonic acid challenge for 5 mins by turbidimetric method Antiplatelet activity in human platelet-rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation treated for 5 mins prior to arachidonic acid challenge for 5 mins by turbidimetric method	[PMID: 24859764]
Platelet	IC₅₀	54 μM Compound: 1, ASA	Antiaggregatory activity in human platelet rich plasma assessed as inhibition of collagen-induced platelet aggregation preincubated for 10 mins before collagen challenge measured after 10 mins by aggregometry Antiaggregatory activity in human platelet rich plasma assessed as inhibition of collagen-induced platelet aggregation preincubated for 10 mins before collagen challenge measured after 10 mins by aggregometry	[PMID: 21906954]
Platelet	IC₅₀	54 μM Compound: 1, ASA	Antiaggregatory activity in plasma rich human platelets assessed as inhibition of collagen-induced platelet aggregation preincubated for 10 mins before collagen challenge measured 10 mins after stimulus addition Antiaggregatory activity in plasma rich human platelets assessed as inhibition of collagen-induced platelet aggregation preincubated for 10 mins before collagen challenge measured 10 mins after stimulus addition	[PMID: 21688846]
Platelet	IC₅₀	58.9 μM Compound: Aspirin	Antiplatelet aggregation activity in New Zealand white rabbit platelet rich plasma assessed as inhibition of ADP-induced aggregation treated for 3 mins before ADP challenge by turbidimetric method Antiplatelet aggregation activity in New Zealand white rabbit platelet rich plasma assessed as inhibition of ADP-induced aggregation treated for 3 mins before ADP challenge by turbidimetric method	[PMID: 23394284]
Platelet	IC₅₀	6.07 μM Compound: Aspirin	Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation treated for 5 mins before ADP challenge measured for 6 mins by microplate reader Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation treated for 5 mins before ADP challenge measured for 6 mins by microplate reader	[PMID: 22137848]
Platelet	IC₅₀	7.07 μM Compound: Aspirin	Antiplatelet activity in New Zealand rabbit platelet-rich plasma assessed as inhibition of ADP-induced aggregation treated for 5 mins prior to ADP-challenge measured after 1 to 6 mins by spectrophotometric analysis Antiplatelet activity in New Zealand rabbit platelet-rich plasma assessed as inhibition of ADP-induced aggregation treated for 5 mins prior to ADP-challenge measured after 1 to 6 mins by spectrophotometric analysis	[PMID: 24565904]
Platelet	IC₅₀	7.7 μM Compound: ASA	Antiplatelet activity in human platelet-rich plasma assessed as inhibition of arachidonic acid-induced aggregation incubated for 5 mins prior to arachidonic acid-challenge measured for 3 mins by turbidrometric analysis Antiplatelet activity in human platelet-rich plasma assessed as inhibition of arachidonic acid-induced aggregation incubated for 5 mins prior to arachidonic acid-challenge measured for 3 mins by turbidrometric analysis	10.1007/s00044-013-0580-x
Platelet	IC₅₀	7.7 μM Compound: ASA	Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 5 mins followed by arachidonic acid addition measured for 3 mins by aggregometric analysis Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 5 mins followed by arachidonic acid addition measured for 3 mins by aggregometric analysis	[PMID: 30108969]
Platelet	IC₅₀	7.76 μM Compound: Aspirin	Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins before arachidonic acid challenge by turbidimetric method Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins before arachidonic acid challenge by turbidimetric method	[PMID: 23639653]
Platelet	IC₅₀	75.4 μM Compound: Aspirin	Antiplatelet aggregatory activity in human platelet rich plasma assessed as inhibition of collagen-induced platelet aggregation by aggregometry Antiplatelet aggregatory activity in human platelet rich plasma assessed as inhibition of collagen-induced platelet aggregation by aggregometry	[PMID: 20056545]
Platelet	IC₅₀	80 μM Compound: ASA	Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced aggregation preincubated for 10 mins before arachidonic acid challenge by aggregometry method Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced aggregation preincubated for 10 mins before arachidonic acid challenge by aggregometry method	[PMID: 22264757]
Platelet	IC₅₀	81 μM Compound: Acetylsalicylic acid	Antiplatelet activity in platelet rich plasma (unknown origin) assessed as inhibition of ADP-induced platelet aggregation incubated for 5 mins by aggregometer analysis Antiplatelet activity in platelet rich plasma (unknown origin) assessed as inhibition of ADP-induced platelet aggregation incubated for 5 mins by aggregometer analysis	[PMID: 37054760]
RAW264.7	IC₅₀	43.2 μM Compound: Aspirin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method	[PMID: 28561586]
SK-BR-3	IC₅₀	> 5000000 nM Compound: ASA	Cytotoxicity against ER deficient human SKBR3 cells after 24 hrs by MTT assay Cytotoxicity against ER deficient human SKBR3 cells after 24 hrs by MTT assay	[PMID: 22916316]
SK-BR-3	IC₅₀	6.93 x 10^-4 M Compound: 1, ASA	Cytotoxicity against human SKBR3 cells after 48 hrs by alamar blue assay Cytotoxicity against human SKBR3 cells after 48 hrs by alamar blue assay	[PMID: 22494617]
SK-BR-3	IC₅₀	7.31 x 10^-4 M Compound: 1, ASA	Cytotoxicity against human SKBR3 cells after 24 hrs by alamar blue assay Cytotoxicity against human SKBR3 cells after 24 hrs by alamar blue assay	[PMID: 22494617]
SW480	IC₅₀	> 5000000 nM Compound: ASA	Cytotoxicity against human SW480 cells expressing COX1 after 24 hrs by MTT assay Cytotoxicity against human SW480 cells expressing COX1 after 24 hrs by MTT assay	[PMID: 22916316]
U-251	EC₅₀	1341 μM Compound: 10	Antiproliferative activity against human U251MG cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human U251MG cells after 72 hrs by sulforhodamine B assay	[PMID: 30568753]
U-87MG ATCC	EC₅₀	723 μM Compound: 10	Antiproliferative activity against human U87MG cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human U87MG cells after 72 hrs by sulforhodamine B assay	[PMID: 30568753]
UACC-903	IC₅₀	> 50 μM Compound: ASA	Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26750401]
UACC-903	IC₅₀	> 50 μM Compound: ASA	Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26750401]
UACC-903	IC₅₀	> 50 μM Compound: ASA	Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26750401]
WI-38	IC₅₀	5.01 x 10^-4 M Compound: 1, ASA	Cytotoxicity against human WI38 cells after 48 hrs by alamar blue assay Cytotoxicity against human WI38 cells after 48 hrs by alamar blue assay	[PMID: 22494617]
WI-38	IC₅₀	6.19 x 10^-4 M Compound: 1, ASA	Cytotoxicity against human WI38 cells after 24 hrs by alamar blue assay Cytotoxicity against human WI38 cells after 24 hrs by alamar blue assay	[PMID: 22494617]

体外研究
(In Vitro)

Aspirin 抑制人关节软骨细胞中的 COX-1 和 COX-2，IC₅₀ 值分别为 3.57 μM 和 29.3 μM^[2]。
Aspirin acetylates COX-1 的丝氨酸 530，从而阻断血小板中血栓素 A 的合成，减少血小板聚集^[3]。
Aspirin 通过干扰 CCAAT/增强子结合抑制 COX-2 蛋白表达蛋白质 beta (C/EBPbeta) 与其在 COX-2 启动子/增强子上的同源位点^[3]。
Aspirin 抑制 NF-κB 依赖性转录自 lgκ 增强子和人类免疫缺陷病毒 (HIV) 转染 T 细胞中的长末端重复序列 (LTR)^[4]。
Aspirin 通过激活半胱天冬酶、激活 p38 MAP 激酶、释放线粒体细胞色素 c、和神经酰胺途径的激活^[6]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Aspirin 可用于诱导胃肠溃疡模型^[8]。

诱导胃肠溃疡模型^[8]

致病原理

Aspirin 可抑制动物内源性前列腺素（PG）的合成。Aspirin 还能溶解粘膜上皮细胞的磷脂，导致粘膜通透性增加。

具体造模方法：

小鼠：白化病小鼠 • 雄性 • 6 周龄
给药方式：500 mg/kg • oral • 单剂量

Note

造模成功指标

组织学改变: 造成表皮上皮细胞的侵蚀。
导致粘膜厚度减少。
无COX-1反应诱发溃疡。

相关产品： /

拮抗产品： /

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male albino Charles River rats (200-250 g, 8 animals/group, fever was induced by 20 ml/kg of a 20 % aqueous suspension of brewer’s yeast which was injected SC in the back below the nape of the neck)^[7]
Dosage:	5, 25, 50, 100 and 150 mg/kg
Administration:	PO, once
Result:	Produced a statistically significant decrease of 0.23 ℃ at 15 min post-drug at the dose of 150 mg/kg. Antipyretic effect gradually increased in magnitude until a peak effect of 1.96 ℃ was reached at 120 min post-drug. The ED50 of aspirin was found to be 10.3 mg/kg with confidence limits of 1.8-23.0 mg/kg. The antipyretic response to aspirin is dependent on the dose of the compound administered.

Animal Model:	Albino male mice ^[8]
Dosage:	500 mg/kg, single dose
Administration:	oral
Result:	Caused erosion of the surface epithelial cells. Resulted in a decrease in the mucosal thickness. Induced ulcer without COX-1 reaction.

Clinical Trial

分子量

180.16

Formula

C₉H₈O₄

CAS 号

50-78-2

性状

固体

颜色

White to off-white

中文名称

阿司匹林；乙酰水杨酸；邻乙酰水杨酸

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性数据

细胞实验：

DMSO 中的溶解度 : 100 mg/mL (555.07 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H₂O 中的溶解度 : 3.12 mg/mL (17.32 mM; ultrasonic and warming and heat to 37°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	5.5507 mL	27.7533 mL	55.5065 mL
5 mM	1.1101 mL	5.5507 mL	11.1013 mL
10 mM	0.5551 mL	2.7753 mL	5.5507 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (13.88 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (13.88 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (13.88 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： Saline
Solubility: 5 mg/mL (27.75 mM); 澄清溶液; 超声助溶
方案二

请依序添加每种溶剂： 50% PEG300 50% Saline
Solubility: 5 mg/mL (27.75 mM); 澄清溶液; 超声助溶

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.82%

选择批次：

Data Sheet (670 KB) SDS (392 KB)

COA (291 KB) LCMS (94 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Mitchell JA, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and induciblecyclooxygenase. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11693-7. [Content Brief]

[2]. Blanco FJ, et al. Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999 Jun;26(6):1366-73. [Content Brief]

[3]. Wu KK, et al. Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med. 2003 May;3(2):107-12. [Content Brief]

[4]. Kopp E, et al. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994 Aug 12;265(5174):956-9. [Content Brief]

[5]. Burch JW, et al. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest. 1978 Feb;61(2):314-9. [Content Brief]

[6]. Elwood PC, et al. Aspirin, salicylates, and cancer. Lancet. 2009 Apr 11;373(9671):1301-9. [Content Brief]

[7]. Loux JJ, DePalma PD, Yankell SL. Antipyretic testing of aspirin in rats. Toxicol Appl Pharmacol. 1972 Aug;22(4):672-5. [Content Brief]

[8]. Yomna I Mahmoud, et al. Spirulina ameliorates aspirin-induced gastric ulcer in albino mice by alleviating oxidative stress and inflammation. Biomed Pharmacother. 2019. [Content Brief]

[9]. Zhongzhi Wang, et al. Protective Effects of Ginger against Aspirin-Induced Gastric Ulcers in Rats. Yonago Acta Med. 2011, 54, 1.

Aspirin 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	5.5507 mL	27.7533 mL	55.5065 mL	138.7663 mL
	5 mM	1.1101 mL	5.5507 mL	11.1013 mL	27.7533 mL
	10 mM	0.5551 mL	2.7753 mL	5.5507 mL	13.8766 mL
	15 mM	0.3700 mL	1.8502 mL	3.7004 mL	9.2511 mL
DMSO	20 mM	0.2775 mL	1.3877 mL	2.7753 mL	6.9383 mL
	25 mM	0.2220 mL	1.1101 mL	2.2203 mL	5.5507 mL
	30 mM	0.1850 mL	0.9251 mL	1.8502 mL	4.6255 mL
	40 mM	0.1388 mL	0.6938 mL	1.3877 mL	3.4692 mL
	50 mM	0.1110 mL	0.5551 mL	1.1101 mL	2.7753 mL
	60 mM	0.0925 mL	0.4626 mL	0.9251 mL	2.3128 mL
	80 mM	0.0694 mL	0.3469 mL	0.6938 mL	1.7346 mL
	100 mM	0.0555 mL	0.2775 mL	0.5551 mL	1.3877 mL

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

Aspirin (Synonyms: 阿司匹林; Acetylsalicylic Acid; ASA)

Customer Review

Other Forms of Aspirin:

MCE 顾客使用本产品发表的 21 篇科研文献

Aspirin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 COX 亚型特异性产品:

查看 NF-κB 亚型特异性产品:

查看 Caspase 亚型特异性产品:

查看 p38 MAPK 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Aspirin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Aspirin (Synonyms: 阿司匹林; Acetylsalicylic Acid; ASA)

Customer Review

Other Forms of Aspirin:

Aspirin 相关抗体

MCE 顾客使用本产品发表的 21 篇科研文献

Aspirin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 COX 亚型特异性产品:

查看 NF-κB 亚型特异性产品:

查看 Caspase 亚型特异性产品:

查看 p38 MAPK 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Aspirin 相关抗体:

摩尔计算器

稀释计算器

Aspirin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z